Lumen Bioscience discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases-many of which currently lack any effective treatments. The company's unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale and exponentially lower costs than current approaches.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/01/20 | $16,000,000 | Series B |
Avista Development Bioeconomy Capital  Columbia Pacific Capital Management WestRiver Management | undisclosed |
